121 South Orange Avenue
Suite 1500
Orlando, FL 32801
United States
407 377 6695
https://nutriband.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | 200k | N/D | 1974 |
Mr. Gareth Sheridan | Founder, CEO & Director | 200k | N/D | 1990 |
Mr. Gerald Goodman | CFO & Chief Accounting Officer | 160k | N/D | 1948 |
Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics | 179k | N/D | 1966 |
Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer | N/D | N/D | 1970 |
Mr. Michael Myer | President of Pocono Pharmaceutical | 40,6k | N/D | 1985 |
Mr. Tyler Overk | Head of Active Intelligence | N/D | N/D | 1984 |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
L'ISS Governance QualityScore di Nutriband Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.